U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07169942) titled 'Aleniglipron Phase 2 Body Composition Study' on Aug. 20.
Brief Summary: This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks of treatment.
Study Start Date: Aug. 15
Study Type: INTERVENTIONAL
Condition:
Obesity, Overweight, or Chronic Weight Management
Intervention:
DRUG: aleniglipron or placebo
Drug: ale...